向LRBA触发CTLA4降解和抗瘤免疫力,用于癌症免疫疗法
Xiaolu Ge1, Liang Yu2, Lei Zhang1
1Laboratory of Molecular Pharmacology and Drug Discovery, Institute of Chinese Materia Medica, The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine; Shanghai Key Laboratory of Pancreatic Disease, Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China.
对脂聚糖体敏感的色类似蛋白 (LRBA) 缺乏影响抗瘤免疫力. 研究人员开发了针对LRBA的小分子LC427,以增强T细胞存活率并有效地对抗癌症.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对脂聚糖体敏感的色样基蛋白 (LRBA) 缺乏与严重的自身免疫性疾病和细胞毒性T淋巴细胞相关蛋白4 (CTLA4) 损失有关.
- 虽然已知与免疫调节有关,但LRBA在抗瘤免疫中的作用尚不清楚.
研究的目的:
- 研究LRBA在抗瘤免疫中的作用.
- 为癌症免疫治疗开发针对LRBA的小分子.
主要方法:
- 使用高通量选和击中优化来识别针对LRBA的小分子.
- 作用机制涉及评估该分子对CTLA4降解和T细胞存活的影响.
- 在各种小鼠瘤模型中评估了抗瘤疗效,并通过口服给予开发的化合物.
主要成果:
- 发现LRBA与人类患者和小鼠模型中的抗瘤免疫有负面关联.
- 发现了一种名为LC427的小分子,可以抑制LRBA-CTLA4相互作用,促进CTLA4的溶酶体降解,增强T细胞存活率.
- 在小鼠模型中,LC427表现出显著的抗瘤活性和瘤透的CD8+ T细胞的增加.
- 在大肠炎模型中,LC427没有诱导与免疫相关的不良事件,与一些免疫检查点抑制剂不同.
结论:
- 准LRBA是开发新型癌症免疫疗法的有希望和有效策略.
- 小分子LC427显示出作为癌症治疗的治疗剂的潜力,与现有免疫疗法相比,其安全性概况有利.
更多相关视频
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
10:04Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
lncRNA - Long Non-coding RNAs
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
